Unichem Laboratories has received an establishment inspection report from the US health regulator for its formulation manufacturing facility in Ghaziabad.
“The company’s formulations manufacturing facility at Ghaziabad has received an establishment inspection report (EIR) from the USFDA. This receipt indicates the successful closure of the inspection and the queries raised during the audit (Form 483),” Unichem Laboratories said in a BSE filing today.
It further said: “The inspection has now been closed by the USFDA. The inspection was carried out between February 24, 2017 and March 3, 2017.”
The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Unichem shares were trading at Rs 249.50 apiece, up 1.07 per cent from its previous close on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.